Compounds > ezetimibe

Page last updated: 2024-09-04

ezetimibe and clofibric acid

ezetimibe has been researched along with clofibric acid in 19 studies

Compound Research Comparison

Studies (ezetimibe)	Trials (ezetimibe)	Recent Studies (post-2010) (ezetimibe)	Studies (clofibric acid)	Trials (clofibric acid)	Recent Studies (post-2010) (clofibric acid)
2,484	563	1,465	1,429	103	120

Research

Studies (19)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	19 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Denke, MA	1
Ansell, BJ	1
Mosca, L	1
Balbisi, EA	1
Schulz, I	1
Arteaga Ll, A; Maiz G, A; Rigotti R, A	1
Maiques Galán, A	1
Backes, JM; Gibson, CA; Howard, PA	1
Balcerak, M; Broncel, M; Chojnowska-Jezierska, J	1
Bouknight, P; Heffington, M; Mackler, L	1
Doggrell, SA	1
Gadarla, M; Kearns, AK; Thompson, PD	1
Fövényi, J; Gaál, Z; Gyimesi, A; Hídvégi, T; Hosszúfalusi, N; Jermendy, G; Nádas, J; Neuwirth, G; Oroszlán, T; Pánczél, P; Putz, Z; Vándorfi, G; Winkler, G; Wittmann, I	1
Kaye, T	1
Hughes, S	1
Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA	1
Kole, LA	1

Reviews

12 review(s) available for ezetimibe and clofibric acid

Article	Year
Coadministration of multidrug therapy to achieve lipid goals. The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:9 Suppl 7 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Risk Factors	2004
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current atherosclerosis reports, 2005, Volume: 7, Issue:1 Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Niacin; Quinolines	2005
Drugs for lipids. Treatment guidelines from the Medical Letter, 2005, Volume: 3, Issue:31 Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Bile Acids and Salts; Cholesterol; Cholesterol, LDL; Clofibric Acid; Drug Interactions; Ezetimibe; Female; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pregnancy; Triglycerides	2005
Management of dyslipidemia in women in the post-hormone therapy era. Journal of general internal medicine, 2005, Volume: 20, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dietary Supplements; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin; Practice Guidelines as Topic; Triglycerides	2005
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. Medical science monitor : international medical journal of experimental and clinical research, 2006, Volume: 12, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors	2006
[Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Niacin	2006
[Intensive cholesterol lowering therapy to reduce cardiovascular risk]. Revista medica de Chile, 2006, Volume: 134, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles	2006
Optimal lipid modification: the rationale for combination therapy. Vascular health and risk management, 2005, Volume: 1, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Research Design; Treatment Outcome	2005
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:127 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin	2007
FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia. American family physician, 2007, Oct-01, Volume: 76, Issue:7 Topics: Anion Exchange Resins; Azetidines; Clofibric Acid; Evidence-Based Medicine; Ezetimibe; Fatty Acids, Omega-3; Garlic; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Phytotherapy; Plant Preparations	2007
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Reviews on recent clinical trials, 2006, Volume: 1, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
The use of lipid-lowering drug therapy in children and adolescents. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:3 Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome	2009

Other Studies

7 other study(ies) available for ezetimibe and clofibric acid

Article	Year
[New indications and therapeutic objectives for dyslipidemia]. Atencion primaria, 2006, Nov-30, Volume: 38, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Dose-Response Relationship, Drug; Drug Design; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Research Design; Resins, Plant	2006
Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few... Harvard men's health watch, 2005, Volume: 9, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Male; Niacin	2005
Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. The American journal of cardiology, 2008, Jun-15, Volume: 101, Issue:12 Topics: Administration, Oral; Anticholesteremic Agents; Azetidines; Biological Products; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Dietary Supplements; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2008
[Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus]. Orvosi hetilap, 2008, Jul-06, Volume: 149, Issue:27 Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Surveys and Questionnaires; Treatment Outcome; Triglycerides	2008
Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine, 2008, Jul-31, Volume: 359, Issue:5 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Niacin; Simvastatin	2008
On the road to better dyslipidemia outcomes. The Nurse practitioner, 2009, Volume: 34, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Lipid Metabolism; Metabolic Syndrome; Niacin; Physical Examination; Risk Assessment; Risk Factors; Vitamin B Complex	2009
Lipid disorders. JAAPA : official journal of the American Academy of Physician Assistants, 2009, Volume: 22, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Vitamin B Complex	2009